Literature DB >> 10453966

Testosterone and andropause: the feasibility of testosterone replacement therapy in elderly men.

B C Lund1, K A Bever-Stille, P J Perry.   

Abstract

Andropause, a syndrome in aging men, consists of physical, sexual, and psychologic symptoms that include weakness, fatigue, reduced muscle and bone mass, impaired hematopoiesis, oligospermia, sexual dysfunction, depression, anxiety, irritability, insomnia, memory impairment, and reduced cognitive function. Free testosterone levels begin to decline at a rate of 1% per year after age 40 years. It is estimated that 20% of men aged 60-80 years have levels below the lower limit of normal. Although the causal relationship between declining testosterone levels and development of andropause symptoms is not firmly established, administration of testosterone to this population resulted in improvements in many areas. Most studies to date focused on physical benefits of testosterone replacement and failed to assess psychologic symptoms rigorously. Preliminary data suggest that therapy may benefit elderly men with new-onset depression. Testosterone administration is not without problems, the most worrisome being the potential for increased prostate cancer risk. Despite this concern, a limited number of studies administered the hormone weekly for up to 2 years, with only mild increases in prostate-specific antigen over control values. Currently, insufficient evidence, primarily regarding psychologic safety and efficacy, exists to warrant general administration of testosterone to elderly hypogonadal men. Further clinical investigations of this therapy in men with low testosterone levels and andropause symptoms are justified and necessary.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10453966     DOI: 10.1592/phco.19.11.951.31574

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  18 in total

1.  Testosterone increases analgesia, anxiolysis, and cognitive performance of male rats.

Authors:  C A Frye; A M Seliga
Journal:  Cogn Affect Behav Neurosci       Date:  2001-12       Impact factor: 3.282

Review 2.  Mad men, women and steroid cocktails: a review of the impact of sex and other factors on anabolic androgenic steroids effects on affective behaviors.

Authors:  Marie M Onakomaiya; Leslie P Henderson
Journal:  Psychopharmacology (Berl)       Date:  2016-01-12       Impact factor: 4.530

3.  Effect of 3α-anderostanediol and indomethacin on acquisition, consolidation and retrieval stage of spatial memory in adult male rats.

Authors:  Somayeh Assadian Narenji; Nasser Naghdi; Shahrbano Oryan; Kayhan Azadmanesh
Journal:  Iran Biomed J       Date:  2012

4.  Male rats with the testicular feminization mutation of the androgen receptor display elevated anxiety-related behavior and corticosterone response to mild stress.

Authors:  Damian G Zuloaga; Jessica E Poort; Cynthia L Jordan; S Marc Breedlove
Journal:  Horm Behav       Date:  2011-07-23       Impact factor: 3.587

5.  Case scenarios in androgen deficiency.

Authors:  Andrew McCullough
Journal:  Rev Urol       Date:  2003

6.  Androgen replacement therapy in the aging male.

Authors:  Jeremy B Myers; Randall B Meacham
Journal:  Rev Urol       Date:  2003

Review 7.  Depression in aging men: the role of testosterone.

Authors:  Ryan M Carnahan; Paul J Perry
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

8.  3alpha-androstanediol, but not testosterone, attenuates age-related decrements in cognitive, anxiety, and depressive behavior of male rats.

Authors:  Cheryl A Frye; Kassandra L Edinger; Edwin D Lephart; Alicia A Walf
Journal:  Front Aging Neurosci       Date:  2010-04-08       Impact factor: 5.750

Review 9.  Testosterone replacement therapy and prostate cancer: a word of caution.

Authors:  Timothy C Brand; Edith Canby-Hagino; Ian M Thompson
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

Review 10.  Use of transdermal drug formulations in the elderly.

Authors:  Laure-Zoé Kaestli; Anne-Florence Wasilewski-Rasca; Pascal Bonnabry; Nicole Vogt-Ferrier
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.